Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A review of clinical syndromes and treatment approaches in clinical practice

Journal of Clinical Neuromuscular Disease

Volumn 4, Issue 4, 2003, Pages 174-189

  Gorson, Kenneth C ^a   Ropper, Allan H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETIDRONIC ACID; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; PROCAINAMIDE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VACCINE; VITAMIN D;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; AREFLEXIA; ARTHRALGIA; ASEPTIC MENINGITIS; BACKACHE; BONE MARROW SUPPRESSION; CEREBROVASCULAR DISEASE; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; ECZEMA; ELECTROMYOGRAM; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FLUSHING; GINGIVA HYPERPLASIA; HEADACHE; HEART MUSCLE ISCHEMIA; HIRSUTISM; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERVISCOSITY SYNDROME; IMMUNOTHERAPY; INFECTION; INJECTION SITE; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LABORATORY TEST; LEG MUSCLE; LEG PAIN; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE IRRADIATION; MALAISE; MOOD DISORDER; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; PANCREATITIS; PERIPHERAL NERVOUS SYSTEM; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RIGOR; SEIZURE; SEPSIS; SIDE EFFECT; SWEATING; THORAX PAIN; THROMBOCYTOPENIA; TREMOR; VACCINATION;

EID: 1642485196     PISSN: 15220443     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131402-200306000-00004     Document Type: Review

References (132)

1. Gorson KC, Chaudhry V. Chronic inflammatory demyelinating polyneuropathy. In: Ringel S, ed. Current Treatment Options in Neurology. Philadelphia: Current Science Group; 1999;1:251-261.
2. Barohn RJ, Saperstein DS. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Semin Neurol. 1998;18:49-61.
3. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without monoclonal gammopathy. Neurology. 1997;48:321-328.
4. Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-637.
5. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory polyradiculoneuropathy: A clinical and electrophysiological study of 92 cases. Brain. 1987;110:1617-1630.
6. Briani C, Brannagan TH, Trojaborg W, et al. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 1996;6:311-325.
7. Cornblath DR, Asbury AK, Albers JW, et al. Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology. 1991;41:617-618.
8. Dyck PJ, Prineas J, Pollard J. Chronic inflammatory demyelinating polyneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, et al., eds. Peripheral Neuropathy. Philadelphia: WB Saunders; 1993:1498-1517.
9. Pollard JD. Chronic inflammatory demyelinating polyradiculo-neuropathy. Curr Opin Neurol. 2002;15:279-283.
10. Hartung HP, Willison H, Jung S, et al. Auto-immune responses in peripheral nerve. Springer Semin Immunopathol. 1996;18:97-123.
11. Hartung HP. Immune-mediated demyelination. Ann Neurol. 1993;33:563-567.
12. Yan WX, Taylor J, Andrias-Kauba S, et al. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol. 2000;47: 765-775.
13. Yan WX, Archelos JJ, Hartung HP, et al. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculo-neuropathy. Ann Neurol. 2001;50:286-292.
14. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11: 136-141.
15. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). Cochrane Database Syst Rev. 2002;1:CD002062.
16. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 1986;314:461-465.
17. Hahn AF, Bolton CF, Pillay N, et al. Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind sham-controlled, cross-over study. Brain. 1996; 119:1055-1066.
18. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculopathy. Neurology. 2001;56:445-449.
19. Van Schaik IN, Winer JB, de Haan R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2002;2: CD001797.
20. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36: 838-845.
21. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled cross-over study. Brain. 1996;119:1067-1077.
22. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol, 2002;50:195-201.
23. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56:94-96.
24. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (Cellcept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy, and inclusion body myositis. J Neurol Sci. 2001;185:119-122.
25. Hughes R, Sanders E, Hall S, et al. Subacute idiopathic demyelinating polyneuropathy. Arch Neurol. 1992;49:612-616.
26. Barohn RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878-884.
27. Dalakas MC, Engel WK. Chronic relapsing (disimmune) polyneuropathy: Pathogenesis and treatment. Ann Neurol. 1981;9 (suppl):134-145.
28. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve. 1997;20:1008-1015.
29. Lunn MPT, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: A prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66:677-680.
30. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24:311-324.
31. Frohman EM, Tusa R, Mark AS, et al. Vestibular dysfunction in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:529-535.
32. Hoffman D, Gutmann L. The dropped head syndrome with chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 1994;17:808-810.
33. Simmons Z, Tivakaran S. Acquired demyelinating potyneuropathy presenting as a pure clinical sensory syndrome. Muscle Nerve. 1996;19:1174-1176.
34. Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: Chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992;55:677-680.
35. Ohkoshi N, Harada K, Nagata H, et al. Ataxic form of chronic demyelinating polyradiculoneuropathy: Clinical features and pathological study of the sural nerves. Eur Neurol. 2001;45: 241-248.
36. Yato M, Ohkoshi N, Sato A, et al. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2000;7:227-230.
37. Rotta FT, Sussman AT, Bradley WG, et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2000;173:129-139.
38. Sabatelli M, Madia F, Mignogna T, et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001; 248:772-777.
39. Lewis RA, Summer AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982;32:958-964.
40. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: The Lewis-Summer syndrome. Muscle Nerve. 1999;22:560-566.
41. Gorson KC, Ropper AH, Weinberg DH. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 1999;22:758-765.
42. Thomas PK, Claus D, Jaspert A. Focal upper limb demyelinating neuropathy. Brain. 1996;119:765-774.
43. Goldstein JM, Parks BJ, Mayer PL, et al. Nerve root hypertrophy as a cause of lumbar stenosis in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1996; 19: 892-896.
44. Schady W, Goulding PJ, Lecky BRF, et al. Massive nerve root enlargement in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1996;61:636-640.
45. Pieh C, Rossillion B, Heritier-Barras AC, et al. Isolated unilateral adduction deficit and ptosis as the presenting features of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroophthalmol. 2002;22:92-94.
46. Guibord N, Chalk C, Win F, et al. Trigeminal nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1998;51:1459-1462.
47. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54:615-620.
48. Oh SJ. Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol. 1978;35:509-516.
49. Mori K, Hattori N, Sugiura M, et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology. 2002;58:979-982.
50. Grand'Maison F, Feasby TE, Hahn AF, et al. Recurrent Guillain-Barré syndrome. Brain. 1992;115:1093-1106.
51. Thomas PK, Lascelles RG, Hallpike JF, et al. Recurrent and chronic relapsing Guillain-Barré polyneuritis. Brain. 1969;92: 589-606.
52. Uncini A, DiMuzio A, De Angelis MV, et al. Minimal and asymptomatic chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 1999;110:694-698.
53. Simmons Z, Albers JW, Bromberg MB, et al. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyneuropathy: Comparison of patients without and with monoclonal gammopathy. Neurology. 1993;43:2202-2209.
54. Kyle RA, Dyck PJ. Neuropathies associated with monoclonal gammopathies. In: Dyck PJ, Thomas PK, Griffin JW, et al., eds. Peripheral Neuropathy. Philadelphia: WB Saunders; 1993:1275-1287.
55. Gorson KC. The clinical features, evaluation and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance. J Clin Apheresis. 1999; 14:149-153.
56. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med. 1998;338:1601-1607.
57. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991;325:1482-1486.
58. Gorson KC, Ropper AH, Weinberg DH, et al. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol. 2002;59:766-772.
59. Suarez GA, Kelly JJ Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: Further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology. 1993;43:1304-1308.
60. Gorson KC, Ropper AH, Weinberg DH, et al. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001;24:778-786.
61. Amato AA, Barohn RJ, Sahenk Z, et al. Polyneuropathy complicating bone marrow transplantation. Neurology. 1993;43: 1513-1518.
62. Rechthand E, Cornblath DR, Stern BJ, et al. Chronic demyelinating polyneuropathy in systemic lupus erythematosus. Neurology. 1984;34:1375-1377.
63. Stewart JD, McKelvey R, Durcan L, et al. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci. 1996;142:59-64.
64. Gorson KC, Ropper AH, Adelman LS, et al. The influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2000;23:37-43.
65. Bird SJ, Brown MJ, Shy ME, et al. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology. 1996;46:822-824.
66. Pritchard J, Mukherjee R, Hughes RAC. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunization. J Neurol Neurosurg Psychiatry. 2002;73:343-350.
67. Arguedas MR, McGuire BM. Hepatocellular carcinoma presenting with chronic inflammatory demyelinating polyradiculo-neuropathy. Dig Dis Sci. 2000;45:2369-2373.
68. Patwa H, Fecko JF, Goldstein JM. Concurrent myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 1996;19:1059-1060.
69. Erdem S, Freimer ML, O'Dorisio T, et al. Procainamide-induced chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1998;50:824-825.
70. Antoine JC, Mosnier JF, Lapras J. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry. 1996;60:188-190.
71. Wu AD, Russell JA, Bouthout BA. Chronic inflammatory demyelinating polyneuropathy and membranous glomerulonephropathy: Report of two cases. J Clin Neuromuscul Dis. 2001;3: 70-74.
72. Mendell JR, Kolkin S, Kissel JT, et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1987;37:1291-1294.
73. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve. 2000;23:433-435.
74. Segurado OG, Kruger H, Mertens HG. Clinical significance of serum and CSF findings in the Guillain-Barré syndrome and related disorders. J Neurol. 1986;233:202-208.
75. Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features. Muscle Nerve. 1989;12:435-451.
76. Olney RK. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve. 1999;22(suppl 8):225-229.
77. Nicolas G, Maisonobe T, Le Forestier N, et al. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002;25: 26-30.
78. Molenaar DSM, Vermeulen M, de Haan RJ. Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2002;249:400-403.
79. Bromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve. 1991;14:968-976.
80. Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurology. 2003;60(suppl 3):S8-S15.
81. Menkes DL, Hood DC, Ballesteros RA, et al. Root stimulation improves the detection of acquired demyelinating polyneuropathies. Muscle Nerve. 1998;21:298-308.
82. Rhee EK, England JD, Sumner AJ. A computer simulation of conduction block: Effects produced by actual block versus interphase cancellation. Ann Neurol. 1990;28:146-156.
83. Haq RU, Fries TJ, Pendlebury WW, et al. Chronic inflammatory demyelinating polyradiculoneuropathy. A study of proposed electrodiagnostic and histologic criteria. Arch Neurol. 2000;57:1745-1750.
84. Krendel DA, Parks HP, Anthony DA, et al. Sural nerve biopsy in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1989;12:257-264.
85. Nagamatsu M, Terao S, Misu K, et al. Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1999;66:727-733.
86. Vital C, Vital A, Lagueny A, et al. Chronic inflammatory demyelinating polyneuropathy: Immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct Pathol. 2000;24:363-369.
87. Bosboom WMJ, van den Berg LH, Franssen H, et al. Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain. 2001;124:2427-2438.
88. Molenaar DSM, Vermeulen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1998;64:84-89.
89. Andrade R, Gonzalez I, Machado A, et al. Can sural nerve biopsy be used to orientate the treatment of chronic inflammatory demyelinating polyneuropathy? Rev Neurol. 2001;33:1005-1009.
90. Pestronk A, Florence J, Miller T, et al. Treatment of IgM anti-body associated polyneuropathies using Rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485-489.
91. van Doorn PA, Vermeulen M, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991;48: 217-220.
92. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous gammaglobulin. Q J Med. 1995;88:493-502.
93. Ropper AH. Current treatments for CIDP. Neurology. 2003;60(suppl 3):S16-S22.
94. Wertman E, Argov Z, Abrmasky O. Chronic inflammatory demyelinating polyradiculoneuropathy: Features and prognostic factors with glucocorticoid therapy. Eur Neurol. 1988;28:199-204.
95. Dyck PJ, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology. 1985;35:1173-1176.
96. Molenaar DS, van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: A pilot study. J Neurol Neurosurg Psychiatry. 1997;62:388-390.
97. Koski CL. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: Pathogenesis and treatment. Semin Neurol. 1994;14:123-130.
98. Pollard JD, McLeod JG, Gatenby P, et al. Prediction of response to plasma exchange in chronic relapsing polyneuropathy: A clinical-pathological correlation. J Neurol Sci. 1983;58:269-287.
99. Palmer KNY. Polyradiculoneuropathy treated with cytotoxic drugs. Lancet. 1966;1:265.
100. Pentland B. Azathioprine in chronic relapsing idiopathic polyneuropathy. Postgrad Med J. 1980;56:734-735.
101. Hughes RAC. Chronic inflammatory demyelinating polyneuropathy. In: Hughes RAC, ed. Guillain-Barré Syndrome. London: Springer-Verlag; 1990:205-246.
102. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci. 1976;27:427-458.
103. Rosen AD, Vastola EF. Clinical effects of cyclophosphamide in Guillain-Barré polyneuritis. J Neurol Sci. 1976;30:179-187.
104. Fowler H, Vulpe M, Marks G, et al. Recovery from chronic progressive polyneuropathy after treatment with plasma exchange and cyclophosphamide. Lancet. 1979;2:1193.
105. Barnett MH, Pollard JD, Davies L, et al. Cyclosporine A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1998;21:454-460.
106. Mahattanakul W, Crawford TO, Griffin JW, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporine-A. J Neurol Neurosurg Psychiatry. 1996;60:185-187.
107. Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporine A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 1990;53:327-330.
108. van Doorn PA, Brand A, Strengers PFW, et al. High dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology. 1990;40:209-212.
109. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle Nerve. 1999;22:1479-1497.
110. Grillo JA, Gorson KC, Lewis J, et al. Complications of rapid infusion intravenous immune globulin (IVIG) in neuromuscular disorders. Neurology. 2001;57:1699-1701.
111. Cocito D, Ciaramitaro P, Isoardo G, et al. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol. 2002;249:719-722.
112. Sharma KR, Cross J, Ayyar DR, et al. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol. 2002;59:751-757.
113. Brannagan TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 1996;47:674-677.
114. Bertorini TE, Nance AM, Horner LH, et al. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve. 1996;19:388-391.
115. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249-1252.
116. Good JL, Chehrenama M, Mayer RF, et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51:1735-1738.
117. Brannagan TH, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58:1856-1858.
118. Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2002; 72:127-128.
119. Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon alpha 2a. Neurology. 1998;50:84-87.
120. Sabatelli M, Mignona T, Lippi G, et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1995;58: 638-639.
121. Pavesi G, Cattaneo L, Marbini A, et al. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating neuropathy. J Neurol 2002;249:777-779.
122. Gorson KC, Allam G, Simovic D, et al. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology. 1997;48:777-780.
123. Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 1995;242:252-253.
124. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon-B1a in chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;53:1364-1365.
125. Hadden RDM, Sharrack B, Bensa S, et al. Randomized trial of interferon B-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999;53:57-61.
126. Vallat JM, Hahn AF, Leger JM, et al. Interferon beta 1a as an investigational treatment for CIDP. Neurology. 2003;60(suppl 3):S23-S28.
127. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy. 1997;17:1178-1197.
128. Gorson KC, Ropper AH. Mycophenolate mofetil (Cellcept®) in patients with immune neuropathy. Neurology. 2003;60(suppl 1):A491.
129. Rosenberg NL, Lacy JR, Kennaugh RC, et al. Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation. Muscle Nerve. 1985;8:223-232.
130. Simmons Z, Albers JW, Bromberg MB, et al. Long-term followup of patients with chronic inflammatory demyelinating polyradiculoneuropathy, with and without monoclonal gammopathy. Brain 1995;359-368.
131. Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;52:498-503.
132. Sghirlanzoni A, Solari A, Ciano, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: Long-term course and treatment of 60 patients. Neurol Sci. 2000;21:31-37.